SCHEMBL12419263

SCHEMBL12419263

CB(O)c1cc2c(OCc3ccccc3)cccc2n1C

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LIPE Q05469 1/20 0.48
▸ MAPT P10636 1/20 0.44
▸ MAPK1 P28482 1/20 0.44
▸ TDP1 Q9NUW8 1/20 0.44
▸ L3MBTL1 Q9Y468 1/20 0.44
▸ SRD5A2 P31213 3/20 0.41
▸ ROCK1 Q13464 1/20 0.41
▸ ENPP2 Q13822 1/20 0.41
▸ SRD5A1 P18405 1/20 0.40
▸ F9 P00740 1/20 0.40
▸ F10 P00742 1/20 0.40
▸ RHEB Q15382 1/20 0.40
▸ MRGPRX4 Q96LA9 4/20 0.40
▸ BRD4 O60885 2/20 0.40
▸ MEN1 O00255 2/20 0.39
▸ NPC1 O15118 2/20 0.39
▸ RAB9A P51151 2/20 0.39
▸ KMT2A Q03164 2/20 0.39
▸ AS3MT Q9HBK9 1/20 0.38
▸ MAOB P27338 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12260288 0.91 LIPE (0.52) LIPEMAPTMAPK1TDP1L3MBTL1
SCHEMBL17355640 0.79 TRPV3 (0.49) LIPESRD5A2MRGPRX4
SCHEMBL5005325 0.78 SRD5A2 (0.61) MAPTMAPK1TDP1L3MBTL1SRD5A2
SCHEMBL27513302 0.76 SRD5A2 (0.53) MAPTMAPK1TDP1L3MBTL1SRD5A2
SCHEMBL4998185 0.76 SRD5A2 (0.50) MAPTMAPK1TDP1L3MBTL1SRD5A2
SCHEMBL27497404 0.75 MAPT (0.45) LIPEMAPTMAPK1TDP1L3MBTL1
SCHEMBL12803818 0.75 MAPT (0.45) LIPEMAPTMAPK1TDP1L3MBTL1
SCHEMBL7877768 0.75 SRD5A2 (0.52) MAPTMAPK1TDP1L3MBTL1SRD5A2
SCHEMBL4997665 0.73 SRD5A2 (0.47) MAPTMAPK1TDP1L3MBTL1SRD5A2
SCHEMBL5132653 0.73 MAPT (0.53) MAPTSRD5A2SRD5A1F10NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150368278-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY PHARMACEUTICALS, INC. (US) 2015-12-24 — — US disclosed
US-8957049-B2 Inhibitors of fatty acid amide hydrolase INFINITY PHARMACEUTICALS, INC. (US) 2015-02-17 — — US disclosed
US-20110172186-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY PHARMACEUTICALS, INC. 2011-07-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110172186-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE FAAH, FAAH2, ASAH1 LIPE 65/4885MAPT 3395/4885MAPK1 3568/4885
US-20150368278-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE FAAH, FAAH2, ASAH1 LIPE 65/4885MAPT 3395/4885MAPK1 3568/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback